{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:09:14Z","timestamp":1765609754869,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-14-1-0161"],"award-info":[{"award-number":["W81XWH-14-1-0161"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Athena Distinguished Professorship of Breast Cancer Research","award":["P50 CA083636, U01 CA154967"],"award-info":[{"award-number":["P50 CA083636, U01 CA154967"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ygyno.2017.01.008","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T21:30:47Z","timestamp":1484256647000},"page":"480-485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer"],"prefix":"10.1016","volume":"144","author":[{"given":"John B.","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron E.","family":"Swensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsie J.","family":"Ovenell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie M.","family":"Hitchcock-Bernhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica L.","family":"Reichow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjun C.","family":"Apodaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen M.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara J.","family":"Buening","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary L.","family":"Disis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ygyno.2017.01.008_bb0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1758834014544121","article-title":"Treatment options in recurrent ovarian cancer: latest evidence and clinical potential","volume":"6","author":"Luvero","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.01.008_bb0010","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.immuni.2013.08.025","article-title":"Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2","volume":"39","author":"Cui","year":"2013","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ygyno.2017.01.008_bb0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"51","key":"10.1016\/j.ygyno.2017.01.008_bb0020","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.ygyno.2017.01.008_bb0025","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2002.09.130","article-title":"Phase II trial of weekly single-agent paclitaxel in platinum\/paclitaxel-refractory ovarian cancer","volume":"20","author":"Markman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2017.01.008_bb0030","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","article-title":"Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement","volume":"14","author":"Garnett","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.ygyno.2017.01.008_bb0035","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1158\/1078-0432.CCR-10-0733","article-title":"A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers","volume":"16","author":"Kodumudi","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2017.01.008_bb0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ijc.11379","article-title":"Granulocyte\/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients","volume":"107","author":"Kiertscher","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.01.008_bb0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2051-1426-2-11","article-title":"Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma","volume":"2","author":"Kaufman","year":"2014","journal-title":"J. Immunother. Cancer"},{"issue":"34","key":"10.1016\/j.ygyno.2017.01.008_bb0050","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2015.62.0500","volume":"33","author":"Lawson","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2017.01.008_bb0055","doi-asserted-by":"crossref","first-page":"8456","DOI":"10.1158\/0008-5472.CAN-03-3251","article-title":"Local administration of granulocyte\/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma","volume":"64","author":"Vuylsteke","year":"2004","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ygyno.2017.01.008_bb0060","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bjc.2011.127","article-title":"Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel","volume":"104","author":"Uzoh","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2017.01.008_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4161\/cbt.5.2.2333","article-title":"Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells","volume":"5","author":"Chakrabarty","year":"2006","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.ygyno.2017.01.008_bb0070","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ygyno.2015.04.039","article-title":"TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas","volume":"138","author":"Seagle","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"7353","key":"10.1016\/j.ygyno.2017.01.008_bb0075","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ygyno.2017.01.008_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13058-015-0663-3","article-title":"Insulin-like growth factor 1 receptor expression and IGF1R 3129G>T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)","volume":"18","author":"de Groot","year":"2016","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2017.01.008_bb0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.canlet.2014.08.023","article-title":"IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells","volume":"354","author":"Singh","year":"2014","journal-title":"Cancer Lett."},{"issue":"29","key":"10.1016\/j.ygyno.2017.01.008_bb0090","doi-asserted-by":"crossref","first-page":"45352","DOI":"10.18632\/oncotarget.9977","article-title":"PRAME expression and promoter hypomethylation in epithelial ovarian cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ygyno.2017.01.008_bb0095","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ygyno.2007.05.008","article-title":"Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials","volume":"106","author":"Harrison","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2017.01.008_bb0100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0197-2456(00)00058-1","article-title":"Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint","volume":"21","author":"Mick","year":"2000","journal-title":"Control. Clin. Trials"},{"issue":"5","key":"10.1016\/j.ygyno.2017.01.008_bb0105","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125","volume":"14","author":"Rustin","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2017.01.008_bb0110","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2017.01.008_bb0115","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/1078-0432.CCR-06-2083","article-title":"Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming","volume":"13","author":"Dang","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2017.01.008_bb0120","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10549-013-2577-z","article-title":"T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity","volume":"139","author":"Cecil","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.ygyno.2017.01.008_bb0125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ygyno.2011.03.036","article-title":"A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"122","author":"Coleman","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.01.008_bb0130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2012.08.039","article-title":"Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma","volume":"128","author":"Tillmanns","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.01.008_bb0135","series-title":"The Department of Defense Era of Hope Conference; Orlando, FL","article-title":"Vaccination with peptides in IGF-IR that induce robust Th1 immunity with limited immunosuppression significantly inhibit tumor growth in a model of triple negative breast cancer","author":"Cecil","year":"2011"},{"issue":"34","key":"10.1016\/j.ygyno.2017.01.008_bb0140","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4 Suppl 2","key":"10.1016\/j.ygyno.2017.01.008_bb0145","first-page":"23","article-title":"Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma","volume":"19","author":"Kurbacher","year":"2005","journal-title":"Oncology (Williston Park)"},{"issue":"334","key":"10.1016\/j.ygyno.2017.01.008_bb0150","doi-asserted-by":"crossref","first-page":"334ra52","DOI":"10.1126\/scitranslmed.aad8307","article-title":"Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses","volume":"8","author":"Welters","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2017.01.008_bb0155","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-13-2774","article-title":"GM-CSF production by tumor cells is associated with improved survival in colorectal cancer","volume":"20","author":"Nebiker","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2017.01.008_bb0160","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1158\/0008-5472.CAN-08-1405","article-title":"Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages","volume":"69","author":"Eubank","year":"2009","journal-title":"Cancer Res."},{"issue":"Suppl. 8","key":"10.1016\/j.ygyno.2017.01.008_bb0165","doi-asserted-by":"crossref","first-page":"viii49","DOI":"10.1093\/annonc\/mdr467","article-title":"Optimal assessment of response in ovarian cancer","volume":"22","author":"Eisenhauer","year":"2011","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2017.01.008_bb0170","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2017.01.008_bb0175","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2017.01.008_bb0180","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ygyno.2011.04.005","article-title":"Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study","volume":"122","author":"Herzog","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.01.008_bb0185","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.5533","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent\/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: safety and clinical activity","volume":"34","author":"Disis","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.01.008_bb0190","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1479-5876-10-33","article-title":"Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes","volume":"10","author":"Milne","year":"2012","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2017.01.008_bb0195","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ygyno.2014.01.026","article-title":"Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer","volume":"132","author":"Williams","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2017.01.008_bb0200","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/JTO.0b013e3181ba2f1d","article-title":"Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin","volume":"4","author":"Karp","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.01.008_bb0205","doi-asserted-by":"crossref","first-page":"e0117745","DOI":"10.1371\/journal.pone.0117745","article-title":"Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients","volume":"10","author":"Heskamp","year":"2015","journal-title":"PLoS One"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581730046X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581730046X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:36:59Z","timestamp":1758771419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581730046X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S009082581730046X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.01.008","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}